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NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author(s) of this 
work have made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author(s) nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author(s) and advisor(s) disclaim all responsibility for the results 
obtained from use of the information contained in this work.  Knowledge and practice 
change constantly, and readers are advised to confirm the information found in this work 
with other more current and/or comprehensive sources. 
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Abstract   
 
Background: Vitiligo is a cutaneous disorder of pigmentation with 1% to 2% incidence. People 
affected by vitiligo have a vast reduction in quality of life caused by the color contrast between healthy 
pigmented skin and depigmented vitiligous patch.   
 
Hypothesis: Topical Immunomodulators are an effective treatment for repigmentation of vitiligo 
patches. 
 
Study Design:  A systematic review of literature 
 
Methods: A literature search was performed using the National Library of Medicine (MEDLINE), 
EMBASE, CINAHL, International Pharmaceutical Abstracts, Current Contents, and search databases.  
Articles included those from 2006-2009, in English-language literature, that were human studies, and 
with the search term using the key word below. 
 
Results: Out of forty eight articles were found in data base, only six articles have the criteria to be 
included in this review. The criteria were controlled trial, and using topical immunomodulators 
(tacrolimus and pimcrolimus) alone for treating vitiligo patches. All six articles are included in this 
review. 
  
Conclusion: Topical immunomodulator ointment is an effective and well-tolerated therapy for vitiligo 
especially involving the head and neck. Larger placebo-controlled studies using calcinerurin inhibitors 
in combination therapy or alone are required to determine the exact role of these drugs in vitiligo 
treatment.  
 
Keywords:  vitiligo, pimecrolimus, tacrolimus, monotherapy 
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The Efficacy of Topical Immunomodulators in Treating Vitiligo 
 
 
Introduction 
 
Vitiligo is an acquired idiopathic hypomelanotic disorder characterized by circumscribed depigmented 
macules.  Histologically, involved skin shows a loss of functional melanocytes and melanin within the 
epidermis. Vitiligo affects people of all races, with an incidence of 1–2% without gender 
predilection.[1]  Vitiligo usually begins in childhood or young adulthood: approximately one-half of 
those with vitiligo, acquire the disease before the age 20.[2]  The course of the disease is usually 
unpredictable, but it is often slowly progressive.  In some patients the lesions may remain static, at 
other times vitiligo may progress rapidly.  Depigmented patches may be present in a localized 
asymmetric form with a focal or segmental distribution or in a generalized symmetric form with an 
acrofacial, disseminated or universal distribution. [3] Although the disease is asymptomatic and does not 
adversely affect mortality and physical morbidity, depigmentation in visible area leads to severe 
cosmetic disfigurement and may be a source of considerable psychological distress.[4]  Patients with 
vitiligo have numerous treatment options available to them, but not all patients respond to current 
treatment methods.  Even among patients who respond to treatment there is a high potential for  
relapse. [5] The development of effective treatment for vitiligo is dependent on an understanding of the 
event leading to depigmentation. However, at present, pathogenesis of vitiligo is not fully understood. 
There are several hypotheses as to the pathogenesis of the disease, but not a single one is fully 
explanatory. [6] There was subtended research in this area prior to 2006 which yield some interesting 
results which appear in Tables 2 and 3.   These studies were excluded for purposes of this review but 
may be useful background information. 
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Autoimmune hypothesis 
Autoimmune hypothesis is one of the most important and popular. This hypothesis suggests that 
abnormality of the immune system results in destruction of melanocytes. Substantial new data 
implicate immune mechanisms in the pathogenesis of vitiligo and indicate that vitiligo may share 
common linkages with other autoimmune diseases. Historically, vitiligo has been reported in 
association with a number of autoimmune diseases. Thyroid disorders, in particular Hashimoto 
thyroiditis and Graves’s disease, are most commonly associated with vitiligo. Other associated 
disorders include diabetes mellitus, alopecia areata, pernicious anemia, rheumatoid arthritis, 
autoimmune polyglandular syndrome, and psoriasis. The presence of antibodies on the surface, and 
cytoplasmic melanocyte antigens in the area of vitiligo on the patients, lends additional support to the 
autoimmune hypothesis. These antibodies can induce the destruction of melanocytes grown in culture 
by complement-mediated lyses and antibody-dependent cellular cytotoxicity. In addition,  melanocyte 
antibodies, when passively administered to nude mice grafted with human skin, have a destructive 
effect on melanocytes within the skin graft. Recent studies have provided additional insights into the 
role of cell-mediated immunity in the destruction of melanocytes, suggesting that cytotoxic T 
lymphocytes may play a significant role in melanocyte destruction in vitiligo. [8]  
Medical therapies for vitiligo 
Vitiligo has been and remains a difficult disease to treat. Previously, therapeutic options have included 
administration of oral and topical psoralen photochemotherapy, topical steroids, and depigmentation 
therapies. At best, none of these treatment options have been optimal. [9] Study outcomes have varied 
considerably given differences in inclusion criteria and scoring systems used to assess repigmentation. 
Recently, a vitiligo Area Scoring Index was developed as a quantitative tool to evaluate vitiligo 
responses parametrically. [7] The scale is based on the degree of macular repigmentation within lesions 
over time and was validated against physician and patient global assessments. Additional studies will 
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be necessary to validate this scoring system. During the past six years, there have been several new 
advances in the treatment of vitiligo. These new treatment options include narrowband UV-B 
phototherapy, targeted light therapy, topical immunomodulators, and calcipotriol in combination with 
UV light. 
Topical Immunomodulators 
Topical Immunomodulators are novel therapeutic agents that act via immunologic pathways either to 
suppress or to enhance immune and inflammatory reaction in the skin. The inhibitory topical 
immunomodulators, tacrolimus and pimecrolimus, are used for treatment of vitiligo. The primary 
mechanism of action in these drugs for the treatment of vitiligo involves calcineurin inhibition 
(calcineurin inhibitors are drugs that were primarily developed for use in transplantation medicine), 
which leads to downregulation of antigen-specific T-cell reactivity and interruption of the transcription 
of genes for a range of proinflammatory cytokines important in the pathophysiology of the early 
immune response.[10] Additional mechanisms may include actions on other important cells in the 
pathophysiology of vitiligo such as dendritic cells, mast cells, keratinocytes, basophils and eosinophils. 
Unlike topical corticosteroids, these drugs do not interfere with collagen synthesis or induce skin 
atrophy. Tolerance for these drugs is good because there is minimal systemic absorption from the 
ointment; topical tacrolimus 0.03% or 0.1% is not associated with the adverse events that have been 
observed with the oral administration of the drug. Treatment with ointment was generally well 
tolerated in short-term (3- to 12-week) and long-term (12- and 24-month) clinical trials. Related 
adverse events were mostly associated with the application site (skin burning or pruritus), were mild  
or moderate and tended to diminish during the first week of, or early in, treatment as the lesions 
 healed. [11] 
Methods 
A literature search was performed using the National Library of Medicine (MEDLINE), EMBASE, 
CINAHL, International Pharmaceutical Abstracts, Current Contents, and Search databases from 2006-
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2009 , English-language literature, Human study, with the search term using the key word “Vitiligo”, 
“Pimecrolimus”, “Tacrolimus”, “monotherapy”. Articles reporting the use of pimecrolimus or 
tacrolimus, monotherapy for treating vitiligo in all ages were reviewed. Selected studies comprised 
randomized, vehicle-controlled trials, and pilot studies of topical pimecrolimus and tacrolimus for 
treating vitiligo.  
Results 
Six studies were found which included in this review. These studies were presented based on the recent 
publish year.  
The first study was conducted by Ai.-E Xu Department of Dermatology Third Hospital of Hangzhou 
Hangzhou China, (2009). [12] They sought to assess the efficacy of topical tacrolimus ointment in the 
treatment of vitiligo. This  prospective pilot study was performed of 30 patients with vitiligo. Patients 
were treated with tacrolimus ointment for at least four months. Clinical responses were documented 
during clinic visits, and by pretacrolimus and post-tacrolimus photography. Twenty five (83.3%) 
patients showed some repigmentation at the end of 4 months. Patients with vitiligo for more than five 
years also responded well to tacrolimus ointment. Repigmentation in active vitiligo was superior to 
that in stable vitiligo. 80% of patients with segmental vitiligo of the head and neck showed some 
response to tacrolimus, but there was no statistical significance between segmental and vulgaris 
vitiligo. The mean percentage of repigmentation on the head and neck was greater than that on the 
trunk and extremities. Four patients initially experienced burning on application. The study concluded 
that topical tacrolimus ointment is an effective and well-tolerated alternative therapy for vitiligo 
especially involving the head and neck area. 
 
The second study was done by Hartmann A. Department of Dermatology University of Wurzburg, 
Germany. [13] They evaluated efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo in a 
placebo-controlled 12-month prospective study. They appraised the placebo-controlled application of 
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tacrolimus 1% ointment for up to 12 months in 30 adult patients with vitiligo. By the end of the 
treatment, 17 of the 21 patients with facial lesions (81%) showed repigmentation on the face and neck 
areas (a mean response of 79.4% of surface area). On the extremities, there was almost no effect when 
applying tacrolimus ointment without dressing. However, when using polyurethane foil or 
hydrocolloid dressing for overnight occlusive treatment, moderate to excellent repigmentation could be 
achieved. In discussion, they showed for the first time that occlusion therapy can enhance the effect of 
topical tacrolimus therapy in vitiligo. 
 
The third study was conducted by Beom Joon Kim, M.D., Department of Dermatology, Chung-Ang 
University, Seoul, Korea. [14] They reviewed the treatment of vitiligo with topical immunomodulators 
and topical steroids, to evaluate the efficacy of immunomodulators in treatment of vitiligo. They 
reviewed 52 patients treated with topical immunomodulators and 27 patients with topical steroids. A 
total of 79 patients were recruited; 38 men and 41 women. The mean age of the 79 patients was 37 
years (range, 2–76). The mean disease duration was 58.8 months (range, 1 month–40 years). Fifty-nine 
patients had lesions on the face, and 53 and 23 patients had lesions on the hand and foot, respectively. 
Fifty-two patients were treated with topical immunomodulators (51 patients were treated with 
tacrolimus ointment, one with pimecrolimus cream) and 27 patients were treated with steroids (23 
patients used a class III topical steroid and four patients were treated with intralesional steroid 
injections). Between gender, mean age, mean disease duration and distribution of lesions, they could 
not find any significant differences in either group. Seventy-nine patients were also divided into three 
groups according to the location of vitiligo lesions. Fifty-nine patients had lesions on the face, and 53 
and 23 patients had lesions on the hand and foot, respectively; 38 patients showed repigmentation on 
the face, 31 on the hands and nine on the foot. However, they could not find any statistically 
significant differences in the ratio of lesions which showed response among these three groups. 
Between the two treatments, the duration from the start of treatment to onset of repigmentation was 
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significantly shorter in the topical immunomodulator group (P = 0.002). However, no statistically 
significant differences were found in gender, age, and mean disease duration, sites of vitiligo lesion 
and ratio of patients who showed response. They suggested topical immunomodulator as an alternative 
to topical steroids for treatment of vitiligo. 
 
The fourth study was been done by N. Sendur, Department of Dermatology, Faculty of Medicine, 
Adnan Menderes University, Turkey.[15] The purpose of their study was to assess the efficacy of 
pimecrolimus cream 1% in vitiligo and to evaluate the effects of age at the patients, age of onset and 
duration of disease on response rate. Twenty-three patients with vitiligo were enrolled in their study; 
19 patients (seven male, 12 female) completed the six-month study period.Patients were treated with 
topical pimecrolimus 1% cream once daily. The response was evaluated as excellent (76–100%), 
moderate (51–75%), mild (26–50%), minimal (1–25%), or no response. The mean age of the 19 
patients was 29.3 (range 7–62 years) and the mean duration of vitiligo was 68.4 months. Three patients 
demonstrated an excellent response to the therapy. Four patients had moderate, six patients had mild 
and five patients had minimal responses; one patient had no response to the treatment. Side effects 
were noted as a burning and stinging sensation in only three patients. The correlations between 
response rate and duration of the disease (r=0.02, p=0.95), onset age (r=-0.17, p=0.48), and age of the 
patients (r=-0.16, p=0.53) were not significant. In conclusion, they found Pimecrolimus has a mild 
therapeutic effect on vitiligo without significant side effects and can be an alternative therapy agent. 
 
The fifth study was conducted by Klaus Wolff, MD, FRCP Department of Dermatology Medical 
University of Vienna, Austria. [16] They performed a double-blinded, intrapatient comparison of 
pimecrolimus cream 1% with placebo cream. They recruited twenty adult Caucasians with 
symmetrical vitiligo predominantly on their extremities, none on the face and treated them twice a day 
for six months left/right with pimecrolimus/vehicle (N = 10) or vehicle/pimecrolimus (N = 10), 
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respectively. Primary efficacy endpoint was the size of the target lesion at month six and secondary 
efficacy endpoint was re-pigmentation. The treatment with pimecrolimus cream 1% or vehicle resulted 
in no significant change in the mean target lesion size. Modest repigmentation (1–25%) was noted with 
pimecrolimus at month 2 in 12 of 17 patients (vehicle: 9 of 17 patients). Afterwards, the number of 
patients who experienced an improvement of pigmentation steadily decreased (3 of 14 patients with 
pimecrolimus and 2 of 14 with placebo at month 6).Treatment was well tolerated. There were no 
treatment-related adverse events, no induction of skin atrophy nor any other application site side 
effects. In this group of adult patients with symmetrical vitiligo, treatment of body lesions (except the 
face) with pimecrolimus cream 1% could not be shown to be effective. 
 
The sixth study has been done by Boone B. Institution Department of Dermatology, University 
Hospital of Ghent, Belgium. [17] They performed an open pilot study in 26 patients to evaluate the 
efficacy and safety of 1% pimecrolimus in the treatment of vitiligo lesions in the head and neck region. 
In 13 of 26 (50%) evaluated target lesions, repigmentation was noted after a six month treatment 
period with a median percentage of repigmentation of 72.9% (interquartile range: 30.5-98.3%). The 
duration of vitiligo and the total affected body surface area tended to be inversely correlated with the 
success rate of treatment. Side effects were mainly limited to a burning sensation at the application 
site.  
Discussion 
In this systemic review study, recent trials (2006-2009) on monotherapy of vitiligo with topical 
immunomodlators such as tacrolimus (Protopic) or pimcrolimus (Elidel) were reviewed. Each of the 
studies examined a different area or population based on their specified study, so no comparison 
between studies can be made and also, each study has strong and negative points which are discussed 
separately below. 
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The first study was a prospective pilot study of response to treatment with tacrolimus ointment in 30 
vitiligo patients. The mean age of the 30 patients was 22.3 ± 7.8 years (range 7–40 years). Forty target 
lesions were selected on which to apply 0.1% ointment twice a day. The majority of the 25 patients 
used tacrolimus ointment to treat only involvement of the head and neck; two patients used the 
tacrolimus ointment to treat vitiliginous sites only on the trunk and/or extremities, and three patients 
applied the tacrolimus ointment for involvement both of head/neck and body/extremities. Twenty-five 
(83.3%) patients showed some repigmentation at the end of four months and the other five patients had 
showed no response. Although this is a good study it has some draw backs. The number of patients 
was small and the duration of treatment was only four months, so definite conclusion cannot be made. 
Clinical studies usually define a successful treatment as when more than 75% repigmentation has been 
achieved and in this study it is not clear what percent reach the point of successful treatment. The other 
issue is number of lesions treated with tacrolimus on the trunk; face and neck were not equal. From 
forty lesions, 25 patient lesions were located in head and neck area and fewer lesions were treated in 
the extremities or trunk. 
The second study was a prospective placebo-controlled right-left comparison study. They investigating 
the efficacy and safety of tacrolimus 0.1% ointment twice a day for up to 12 months in 30 adult 
patients aged between 19 and 65, with vitiligo and also tested the influence of additional occlusive 
treatment. By the end of treatment, 17 of the 21 patients with facial lesions (81%) showed 
repigmentation on the face and neck areas .On the extremities there was almost no effect when 
applying tacrolimus ointment openly. However, when they used polyurethane foil or hydrocolloid 
dressing for overnight occlusive treatment moderate to excellent regimentation occurred. Based on the 
therapeutic appraisal form in placebo-right and left comparison, this study is validated. Unfortunately, 
this study is not blind study so patient knowledge can cause bias.  The number of patients was small, 
so definite statics cannot be obtained. A weakness in this study is that since the age range in those 
tested was 19-65, hell of the population at risk for vetiligo, those under 19 were ignored. 
 15 
 
In the third study, a retrospective review, 52 patients were treated with topical immunomodulators for 
six months and 27 patients with topical steroids, to evaluate the efficacy, of topical 
immunomuodulators compare to topical steroid in treatment of vitiligo. Between the two groups, the 
duration from the start of treatment to onset of repigmentation was significantly shorter in the topical 
immunomodulator group (P = 0.002). However, no statistically significant differences were found in as 
to gender, age, and mean disease duration, sites of vitiligo lesion and ratio of patients who showed 
response. So at six month the result would look alike applying topical immunomodulators or topical 
steroids for more than six months without repigmentation was considered treatment failure. Their 
results showed that topical immunomodulators are as effective as topical steroids in repigmentation. 
This study has a lot of drawbacks; first, they didn’t measure the repigmentaion as mild, moderate or 
excellent and used no measurement scale for repigmentation. They could not unify topical 
immunomodulators and topical steroids, and they could not review side-effects of treatment. 
Moreover, they evaluated efficacy only by repigmentation of vitiligo lesions; they could not evaluate 
the area of repigmentation. Despite these limitations, on the basis of their study, they may suggest 
topical immunomodulators as an alternative for treating vitiligo. 
 
The fourth study is prospective a review; the purpose of this study was to assess the efficacy of 
pimecrolimus cream 1% in vitiligo and to evaluate the effects of age of the patients, age at onset and 
duration of disease, on response rate. Twenty-three patients with vitiligo were enrolled in their study; 
19 patients completed the six-month study period. Patients were treated with topical pimecrolimus 1% 
cream once daily. They found that pimecrolimus has a mild therapeutic effect on vitiligo without 
significant side effects and can be an alternative therapy for treating vitiligo and there were no 
significant correlations between response rate and duration of the disease (r=0.02, p=0.95), age at onset 
of the disease (r=20.17, p=0.48), nor age of the patients (r=20.16, p=0.53). This study has a lot of 
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limitation; first, the number of patients was small, so absolute conclusion cannot be drawn.  The 
limited number of patients for clinical type as of vitiligo was the main limitation of their study. It 
restricted the comparison rates for each clinical type the efficacy of therapy alternatives is variable in 
vitiligo and mostly depends on the clinical type of the disease which was unspecified. The therapeutic 
response is known to be poor in segmental and acrofacial forms. They also had four who patients were 
lost to follow-up which is quite damaging in such a small study; furthermore no clear explanation of 
their loss is given. 
In the fifth study which is a randomized, double blinded, vehicle-controlled study; the purpose of the 
study was to assess the efficacy of pimecrolimus cream 1 % in adult patient with vitiligo. Twenty 
adults with symmetrical vitiligo (predominantly on extremities, none on the face) were treated twice a 
day for six months left/right comparison with pimecrolimus/vehicle (N = 10) or vehicle/pimecrolimus 
(N = 10), respectively. Primary efficacy endpoint was the size of the target lesion at month six and 
secondary efficacy endpoint was repigmentation. They found that in this group of adult patients with 
symmetrical vitiligo, treatment of lesions  on the body (except face) with pimecrolimus cream 1% 
could not be shown to be effective, although there were no treatment-related adverse events, no 
induction of skin atrophy nor any  application site side effects. This study as with the others has 
drawbacks. The number of patient was small, so definite statics cannot be made. Also, four of the 20 
patient didn’t complete the treatment. Pimecrolimus cream 1% is known to be highly effective in 
children and infants with atopic dermatitis with superior results in lesions on the face and neck as 
compared to lesions on the total body surface [18-20]. The comparably poor effect on pigmentation 
observed with pimecrolimus in the present study might, therefore, be explained by the fact that it was 
conducted in adult patients and that almost all lesions treated were localized on the extremities with 
9/20 on the back of the hands. It is likely therefore, that, this study is neither representative true of the 
affected actual population nor the site of the vitiligo. 
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The last study was an open pilot study in 26 patients to evaluate the efficacy and safety of 1% 
pimecrolimus in the treatment of vitiligo lesions in the head and neck region. Subsequently, the 
percentage of area reduction or repigmentation in the reference lesion during the trial was calculated. 
This percentage of repigmentation was the main parameter to measure treatment efficacy. Changes in 
pigmentation were evaluated with a Wilcoxon Ranked Sign test with a p-value less than 0.05 
indicating statistical significance. Clinical assessment revealed repigmentation of the target lesion on 
the face or neck in 38.5% of patients after three months and in 50.0% of patients after six months. 
Objective measurement of the target lesion showed a median relative area reduction of 26.2% and 
72.9% after three and six months respectively. They suggest that using pimecolimus for vitiligo on the 
head and neck is promising shows results but, due to the small sample size of the pilot study no 
statistically significant predictors of response rate could be identified.  However, some tendencies were 
noted. Duration of vitiligo and total affected body surface area influenced treatment outcome. The 
shorter the duration of vitiligo and the smaller the total affected body surface area, the better the 
probability of repigmentation. 
 
A summary of reviewed studies is appears in Table 1 and also a summary of case reports and clinical 
studies on tacrolimus and pimcrolimus in the treatment of vitiligo before 2006 is in table 2-3. In 
general data from case reports and pilot studies investigating the use of topical calcineurin inhibitors in 
the treatment of vitiligo are promising. 
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Conclusion 
Substantial strides have been made in uncovering of the pathogenesis of vitiligo in pursing an effective 
treatment. New, more effective therapies provide renewed hope for patients affected by this disease.  
Until now, many therapies have been used to treat vitiligo; topical and oral steroids, topical and oral 
psoralen photochemotherapy, narrow-band and broad-band ultraviolet-B, calcipotriol, tar and 
vitamins/antioxidants. Despite many kinds of therapies, none are satisfactory completly. After Grimes 
et al and others [21, 22] reported repigmentation induced by tacrolimus in patients with vitiligo, topical 
immunomodulators were widely used to treat it.  Moreover, the lack of atrophogenic potential and lack 
of risk of induction of ocular cataracts or glaucoma with topical immunomodulators make these new 
topical agents appropriate agents for treating vitiligo of children and face or neck lesions or adult 
vitiligo patients.  Also, topical immunomodulators induced faster repigmentation than steroids, and this 
could be an advantage over steroids in treatment of vitiligo.  The size of the studies looked at in this 
review was so small as to render their conclusions unreliable. The sample size will be the key to future, 
successful studies. Each of the studies examined a different area or population and made tentative 
finding based on their specified study. If all of the parameters were combined a conclusive, valid study 
may result. While this is a condition which has mostly psychological repercussions for those suffering 
from outbreaks, it is still vital to address what might be a relatively simple and cost effective solution.  
Larger placebo-controlled studies using calcinerurin inhibitors in combination therapy or alone are 
required to determine the exact role of these drugs in vitiligo treatment.   
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Table 1:  Summary of Review Studies 
 
Author/  Title/ Journal Yr.  
published 
Patients
/  
Populat
ion 
Intervention Comparison Outcome(s) Study type Validity 
(Jadad 
score) 
Comments/ 
result 
Ai-E.Xu/Efficacy and safety of 
tacrolimus cream 0.1% in the 
treatment of 
vitiligo/International Journal 
of Dermatology 
2009 30 Pt Using Topical 
tacrolimus 0.1% 
for four months 
None repigmentation Prospective 
pilot study 
Zero Study one/ 83.3% 
Pt repigmentation 
after four months 
on head and neck 
Anke Hartmann/Occlusive 
Treatment Enhances Efficacy 
of Tacrolimus 0.1% Ointment 
in Adult Patient With Vitiligo: 
results of a Placebo controlled 
prospective study/Acta Derm 
Venereol 88 
2008 30 Pt Using Topical 
tacrolimus 0.1% 
for 12 months 
Not using 
tacrolimus 
repigmentation Prospective 
Placebo-
controlled 
Right and 
left 
camparison 
study 
zero Study two/ 81% Pt  
showed 
repigmentation 
after 12 months in 
facial and neck 
area, no effect on 
the extremities 
lesion 
Beom Joon Kim, M.D.,   
Topical immunomodulators 
are effective for treatment of 
vitiligo/The journal of 
dermatology,volume35,issue8 
2008 52 Pt Using topical 
immunomoduator  
for six months 
compare to 
steroid 
therapy 
repigmentation A 
retrospective 
review 
zero Study three/ 
topical 
immunomodulator 
are as effective as 
topical steroids in 
repigmentation 
Markus dawid/Efficay and 
safety of pimercrolimus cream 
1% in adult patient with 
vitiligo: Results of randomized 
double-blind, vehicle-
controlled study/JDDG 
2006 23 Pt pimercrolimus 
cream 1% for six 
months 
none repegmentation Prospective 
study 
Zero Study four//68.5% 
Pt achieved mild 
to moderate 
repigmentation in 
focal vitiligo 
Neslihan Sender/Topical 
pimecrolimus: A new horizon 
for vitiligo treatment/Journal 
of Dermatological Treatment 
2006 20 Pt pimercrolimus 
cream 1% for six 
months 
Placebo 
cream 
repigmentation Double-
blind-intra 
patient 
2 Study five/no  
effect showed on 
symmetrical  
vitiligo lesion in 
body 
Barbara BOONE /Topical 
pimecrolimus in the treatment 
of vitiligo/Eur J Dermatol 
2007; 17 (1): 55-61 
EJD, vol. 
2007 26 Pt Pimcrolumus 
cream 1% for six 
months 
none repigmentation Open pilot 
study 
Zero Study six/ 50% Pt 
showed moderate 
repigmentation in 
face and neck area 
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Table 2:  Case reports and clinical studies on tacrolimus in the treatment of vitiligo [23] 
 
   Tacrolimus      
Reference Study Design Number 
of 
Patients 
Study 
Duration 
Treatment 
Regimen 
Materials and 
Methods 
Results Adverse 
Effects 
Mehrabi D [42] 
2006 
Randomized, 
placebecontrolled
, double-blind trial 
9 12 weeks 0.1% 
tacrolimus 
+ UVB vs. 
placebo + 
UVB 
2 paired 
vitiligo 
patches, 
digital 
photography, 
computerized 
area  
measurement 
No statistically 
significant 
difference 
Redness, 
pruritus, burning 
(most likely 
related to light 
therapy) 
Ostovari N [43] 
2006 
Comparative 
prospective, non 
blind,  
pilot study 
9 12 weeks 0.1% 
tacrolimus 
+ UVB vs. 
0.1% 
tacrolimus 
2 paired 
vitiligo 
patches,digital 
photography, 
6-point scale 
for 
grading 
repigmentation 
by 2 
investigators 
No 
repigmentation 
with 
tacrolimus  
monotheraphy 
Erythema (most 
likely related to 
light therapy) 
Almeida P [44] 
2005 
Open pilot study 12 8 months 0.1% 
tacrolimus 
twice daily 
Digital 
photography, 
3- 
point, scale tor 
grading 
repigmentation 
Good to 
excellent 
repigmentation 
in 50% of 
patients 
Pruritus at initial  
application 
Kanwar AJ [45] 
2004 
Open pilot study 12 
children 
12 weeks 0.03% 
tacrolimus 
twice daily 
Digital 
photography, 
serial 
mapping of 
body lesions, 
3- 
point, scale tor 
grading 
repigmentation 
Complete 
repigmentation  
in 57.9% of 
patients, best 
results 
in face and 
hear bearing 
sites 
Pruritus and 
burning 
Silverberg N [46] 
2004 
Retrospective 
review 
57 
children 
3 months 0.03% or 
0.1% 
tacrolimus 
once or 
twice daily 
Digital 
photography, 
3- points scale 
for 
grading 
repigmentation 
At least partial 
repigmentation 
in 84% of 
patients, best 
results in head 
and region 
Burning at initial 
application 
Passeron T [17] 
2004 
Comparative, 
prospective, 
randomized, intra-
individual study 
14 12 weeks 0.1% 
tacrolimus 
+ excimer 
laser vs. 
excimer 
laser 
2 to 5 paired 
lesions, digital 
photography, 
6- points scale 
for 
grading 
repigmentation 
Combination 
therapy is 
superior to 
excimer laser 
mootheraphy 
Erythema, 
bullae (most  
likely related to 
light therapy) 
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Table 2:  Case reports and clinical studies on tacrolimus in the treatment of vitiligo [23] Continue: 
 
Reference Study Design Number 
of 
Patients 
Study 
Duration 
Treatment 
Regimen 
Materials and 
Methods 
Results Adverse Effects 
Kawalek A 
[18] 2004 
Prospective, 
doubleblind, 
plaeebocontrolle
d study 
8 10 weeks 0.1% 
tacrolimus 
+ excimer 
laser vs. 
placebo + 
excimer 
laser 
24-symmetric 
patches,photogr
aphy, 4-point 
scale forgrading 
repigmentation 
Significantly 
greater degree 
ofrepigmentatio
n when 
treatmentwith 
combination 
therapy 
Excimer: 
erythema, 
blisteringTacrolimu
s: tingling, 
burning,erythema 
Grimes P 
[10] 2004 
Open 
prospective 
study 
23 24 weeks 0.1% 
tacrolimus 
twice daily 
6-points disease 
severity scale 
Varying levels 
in 89% of 
patients, best 
result head and 
neck region 
Burning, stinging, 
pruritus, 
verruca vulgaris 
Lepe V 
[14] 2003 
Randomized, 
double-blind, 
comparative trial 
20 
children 
2 months 0.1% 
tacrolimus 
vs. 0.05% 
clobetasol 
propionate 
2-symmetrical 
lesions, color 
slides, 
morphometric 
digitalized 
computer 
program 
Tacrolimus 
almost as 
effective 
as clobetasol  
propionate 
Clohetasol 
propionate: 
atrophy, 
telangiectasia 
Tacrolimus: 
burning 
Travis L 
[47] 2003 
Case report 3 2 - 4 
moths 
0.1% 
tacrolimus 
twice daily 
Lesions on face 
and eyelids 
Complete 
repigmentation 
in 
100% of 
patients 
None 
Castanedo
-Cazares 
[48] 2003  
Case report 1 4 months 0.1% 
tacrolimus 
+ UV-B 
Lesions on face Percentage of 
repigmentation 
area: 95% 
Not mentioned 
Tanghetti 
E [49] 
2003 
Open pilot study 15 1.5 - 9.5 
months 
0.1% 
tacrolimus 
twice daily 
[+ sunlight 
exposition 
in some 
pateints] 
4-points scale 
for grading 
overall 
repigmentation 
At least partial 
repigmentation 
in 87% of 
patients 
None 
Grimes 
P[50] 2002 
Open pilot study 6 1 - 5 
months 
0.03% or 
0.1% 
tacrolimus 
twice daily 
Application on 
all vitiliginous 
lesions, 4-points 
scale for 
grading overall 
repigmentation 
Moderate lo 
excellent 
repigmentation 
in 83% of 
patients 
Burning and 
stinging at initial 
application, tinea 
corporis 
Smith D 
P[51] 2002 
Case report 1 18 
months 
0.1% 
tacrolimus 
twice daily 
Lesions on face 90% 
repigmentation 
in face 
and scalp 
region 
Not mentioned 
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Table 3: Case reports and clinical studies on pimecrolimus in the treatment of vitiligo [19] 
 
   Pimecrolimus      
Reference Study 
Design 
Number 
of 
Patients 
Study 
Duration 
Treatment 
Regimen 
Materials and 
Methods 
Results Adverse 
Effects 
Coskun B [16] 
2005 
Comparative 
prospective, 
non-blind 
trial 
10 2 months 1% 
Pimecrolimus 
vs. 0.04% 
Clobetasol 
propionate 
2-paired 
vitiligo 
patches, 
digital 
photography, 
4-points scale 
for grading 
repigmentation 
Comparable 
rate of 
repigmentation 
Clobetasol 
propionate: 
telangiectasia, 
atrophy 
Pimecrolimus: 
burning 
Mayoral F[15] 
2003 
Case report 1 5 months 1% 
Pimecrolimus 
Lessions on 
the face, 
scalp, trunk 
(+atopic 
dermatitis) 
Percentage of 
repigmentation: 
>90% 
None 
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